CSL Behring AG publishes Offer Prospectus on public tender offer for all publicly held shares of Vifor Pharma Ltd.Business Wire • 01/18/22
CSL Seals $11.7B Buyout Deal Of Vifor Pharma, Probably the Largest Healthcare Deal In 2021Benzinga • 12/14/21
New Data Supports the Effectiveness of Adjuvanted Seasonal Influenza Vaccine in Reducing Influenza-Related Hospitalizations and Healthcare Costs in Older AdultsPRNewsWire • 12/07/21
Seqirus Announces U.S. FDA Approval for Multi-Dose Vial Presentation of First-Ever Adjuvanted, Cell-Based Pandemic Influenza VaccinePRNewsWire • 11/23/21
Clinical Trial Milestones, Investments in aQIVc and sa-mRNA Influenza Vaccines and New Strategic Collaborations Among the Highlights from CSL R&D DayPRNewsWire • 10/19/21
CSL Limited's (CSLLY) CEO Paul Perreault on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/18/21
The European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) Task Force Has Strongly Recommended Subcutaneous Immunoglobulin (SCIg) for CIDP Maintenance TreatmentPRNewsWire • 08/09/21
FDA Approves New BERINERT® (C1 Esterase Inhibitor, Human (Intravenous)) Administration Kit for Increased Patient ConveniencePRNewsWire • 08/03/21
Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) To Be Covered Under Medicare Part B Effective July 18, Improving Access and Reducing Out-of-Pocket Costs for CIDP PatientsPRNewsWire • 06/08/21
New Meta-Analysis of Patients with Acute Coronary Syndrome Shows Nearly Half of Recurrent Major Adverse Cardiovascular Events at One Year Occur Within the First 90 DaysPRNewsWire • 05/16/21
Lyfebulb and CSL Behring Announce the Winner of the 2021 Transplant Innovation ChallengePRNewsWire • 05/14/21
CSL Limited (CSLLY) CEO Paul Perreault on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/18/21